A Phase 2 Study of Pemetrexed and Erlotinib for Metastatic Colorectal Cancer Refractory to Standard Chemotherapy

Trial Profile

A Phase 2 Study of Pemetrexed and Erlotinib for Metastatic Colorectal Cancer Refractory to Standard Chemotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Erlotinib (Primary) ; Pemetrexed (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jul 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
    • 15 Jul 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
    • 02 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top